Efficacy and safety of ixazomib maintenance therapy for patients with multiple myeloma: a meta-analysis
H Chen, Y Wang, C Shao, C Sun, C Zheng - Hematology, 2021 - Taylor & Francis
Objectives Multiple myeloma (MM) is a malignant plasma cell disease. Maintenance
treatment is beneficial to prolong survival time in patients with MM. Ixazomib was approved …
treatment is beneficial to prolong survival time in patients with MM. Ixazomib was approved …
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma
PJ Sampat, M Bisen, N Srivastava… - … High Impact Case …, 2021 - journals.sagepub.com
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the
first oral proteasome inhibitor approved in the United States for the management of multiple …
first oral proteasome inhibitor approved in the United States for the management of multiple …